Entrada Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Entrada Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2020 to 2023.
  • Entrada Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$14M, a 140% decline year-over-year.
  • Entrada Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was $55M.
  • Entrada Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$6.69M, a 92.9% increase from 2022.
  • Entrada Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$94.6M, a 84.9% decline from 2021.
  • Entrada Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$51.2M, a 92.9% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$6.69M +$87.9M +92.9% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-13
2022 -$94.6M -$43.5M -84.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-13
2021 -$51.2M -$24.6M -92.9% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-06
2020 -$26.5M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.